表紙
市場調査レポート

米国の固形腫瘍検査市場:2016〜2020年

Solid Tumor Testing Market in the US 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 353218
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
米国の固形腫瘍検査市場:2016〜2020年 Solid Tumor Testing Market in the US 2016-2020
出版日: 2016年02月24日 ページ情報: 英文 50 Pages
概要

固形腫瘍検査またはスクリーニングは癌の早期発見のために行なわれ、全身に癌細胞が広がるのを防ぐための効果的な治療を可能とします。尿や血液などの試料を検査するほか、特定の遺伝子変異を分析するために遺伝子検査が伴う場合もあります。米国の固形腫瘍検査市場は、2016〜2020年にかけCAGR11.1%で拡大すると予測されています。

当レポートでは、米国の固形腫瘍検査市場の現状と今後の成長見通し、市場動向、市場成長への課題、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

  • 市場ハイライト

第5章 米国における医療改革

  • 米国の医療改革が癌検査業界に及ぼす影響

第6章 償還および補償:概要

  • 現在のシナリオ:診断検査の評価
  • 米国における償還構造
  • 償還政策の課題

第7章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 技術別市場セグメンテーション

  • 従来の検査
  • 遺伝子検査

第9章 癌のタイプ別市場セグメンテーション

  • 乳癌
  • 肺癌
  • 大腸癌
  • 前立腺癌
  • 子宮頸癌
  • その他

第10章 市場促進因子

  • 個別化医療への高い需要
  • 医療制度の改正
  • POC検査に対する需要の増大
  • 分子検査の増加

第11章 促進因子の影響

第12章 市場の課題

  • 正確な癌検査キットの不足
  • 法規制の課題
  • 熟練技術者の不足

第13章 促進因子および課題の影響

第14章 市場動向

  • ベンチトップ質量分析器の使用
  • すぐに使える試薬

第15章 ベンダー環境

  • 競合シナリオ
  • 市場シェア:2015年
  • その他の注目すべきベンダー

第16章 付録

第17章 Technavioについて

図表

目次
Product Code: IRTNTR8803

About Solid Tumor Testing Market in the US

Solid tumor testing or screening is done for the early detection of cancer, enabling effective treatment measures to avoid the spread of cancerous cells throughout the body. The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Further, cancer testing also involves conducting genetic tests to analyze certain gene mutations that are linked to certain cancer types. Biopsy, colonoscopy, Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests that are performed for cancer screening.

Technavio's analysts forecast the solid tumor testing market in the US to grow at a CAGR of 11.1% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of solid tumor testing products, such as assays or kits and bench-top instruments.

The market is divided into the following segments based on cancer types:

  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Other (including pancreatic cysts and thyroid nodules)

Technavio's report, Solid Tumor Testing Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Abbott Molecular
  • Agilent Technologies (Dako)
  • Beckman Coulter
  • Roche Diagnostics

Other Prominent Vendors

  • 20/20 GeneSystems
  • Adaptive Biotechnologies
  • Advanced Cell Diagnostics
  • Affymetrix
  • Agena Bioscience
  • Ambry Genetics
  • ApoCell
  • Avant Diagnostics
  • Biological Dynamics
  • Boditech Med
  • Becton, Dickinson and Company (BD)
  • Biocare Medical
  • Bio-Rad Laboratories
  • Castle Biosciences
  • CDx Diagnostics
  • Celerus Diagnostics
  • Cancer Genetics
  • Caris Life Sciences
  • Clarient Diagnostic Services
  • DiaTech Oncology
  • Enzo Biochem
  • Epic Sciences
  • EDP Biotech
  • Eutropics Pharmaceuticals
  • Fujirebio Diagnostics
  • Genalyte
  • Hologic
  • Janssen Diagnostics
  • Myriad Genetics
  • Omnyx
  • OxfordGene Technology
  • Oncospire Genomics
  • OncoCyte
  • OvaGene Oncology
  • Pathway Genomics
  • Quest Diagnostics
  • QIAGEN
  • RiboMed Biotechnologies
  • Sequenom
  • Siemens Healthcare Diagnostics
  • Thermo Fisher Scientific
  • Tosoh Bioscience
  • TrimGen

Market driver

  • High demand for personalized medicines
  • For a full, detailed list, view our report

Market challenge

  • Regulatory issues
  • For a full, detailed list, view our report

Market trend

  • Ready-to-use reagents
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Healthcare reform in US

  • Impact of US healthcare reform on cancer testing industry

PART 06: Reimbursement and coverage: An overview

  • Current scenario: Validating diagnostic tests
  • Reimbursement structure in US
  • Prevailing issues of reimbursement policies

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by technology

  • Conventional testing
  • Genetic testing

PART 09: Market segmentation by cancer type

  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Cervical cancer
  • Other

PART 10: Market drivers

  • High demand for personalized medicines
  • Changes in healthcare system
  • Rise in demand for POC testing
  • Increase in molecular testing

PART 11: Impact of drivers

PART 12: Market challenges

  • Shortage of accurate cancer testing kits
  • Regulatory issues
  • Lack of skilled technicians

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Use of bench-top mass spectrometer
  • Ready-to-use reagents

PART 15: Vendor landscape

  • Competitive scenario
  • Key vendor analysis 2015
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 1: Product offerings
  • Exhibit 2: US healthcare infrastructure before and after healthcare reform
  • Exhibit 3: Positive and negative impact of US healthcare reform on market
  • Exhibit 4: Reimbursement perspective healthcare entitles
  • Exhibit 5: Solid tumor testing market in US
  • Exhibit 6: Solid tumor testing market in US 2015-2020 ($ billions)
  • Exhibit 7: Five forcast analysis
  • Exhibit 8: Segmentation of solid tumor testing market in US by technology 2015
  • Exhibit 9: Segmentation of solid tumor testing market in US by technology 2020
  • Exhibit 10: Segmentation of solid tumor testing market in US by technology 2015-2020
  • Exhibit 11: Solid tumor conventional testing market in US 2015-2020 ($ billions)
  • Exhibit 12: Solid tumor generic testing market in US 2015-2020 ($ billions)
  • Exhibit 13: Segmentation of solid tumor testing market in US by cancer type
  • Exhibit 14: Segmentation of solid tumor testing market in US by cancer type 2015
  • Exhibit 15: Segmentation of solid tumor testing market in US by cancer type 2020
  • Exhibit 16: Segmentation of solid tumor testing market in US by cancer type 2015-2020
  • Exhibit 17: Solid tumor testing market in US for breast cancer 2015-2020 ($ billions)
  • Exhibit 18: Solid tumor testing market in US for lung cancer 2015-2020 ($ billions)
  • Exhibit 19: Solid tumor testing market in US for colorectal cancer2015-2020 ($ billions)
  • Exhibit 20: Solid tumor testing market in US for prostate cancer 2015-2020 ($ millions)
  • Exhibit 21: Solid tumor testing market in US for cervical cancer 2015-2020 ($ millions)
  • Exhibit 22: Solid tumor testing market in US for other cancers 2015-2020 ($ millions)
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Abbott Molecular: Key takeaways
  • Exhibit 26: Agilent Technologies (Dako): Key takeaways
  • Exhibit 27: Beckman Coulter: Key takeaways
  • Exhibit 28: Roche Diagnostics: Key takeaways
Back to Top